A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Subjects With Parkinson`s Disease and Motor Fluctuations
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2018
Price : $35 *
At a glance
- Drugs Tavapadon (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 04 Apr 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 07 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 Mar 2016, according to ClinicalTrials.gov record.